Search results
Wegovy and Other New Weight Loss Drugs Actually Work—so What's Next?
Gizmodo via Yahoo News· 4 months agoFew prescription drugs have entered the public consciousness as abruptly as Ozempic and Wegovy have...
New uses for old drugs? Every Cure offers hope for people with rare diseases
USA TODAY via Yahoo News· 2 years agoEvery drug on the market has multiple effects on the body, not just the one or two that won it...
Pharma lobbying for weight loss drugs could soon pay off
Yahoo Finance· 9 months agoThe recent surge in popularity of weight loss and Type 2 diabetes drugs Wegovy, Ozempic, and...
Amazon launches a subscription prescription drug service
KIRO via Yahoo News· 1 year agoAmazon is adding a prescription drug discount program to its growing health care business. The...
The Supreme Court Just Took on Abortion Again. It Won’t End Well.
Slate via Yahoo News· 5 months agoThis is part of Opening Arguments, Slate’s coverage of the start of the latest Supreme Court term....
Unraveling Viatris Inc's Potential Underperformance: A Deep Dive into the GF Score
GuruFocus.com via Yahoo Finance· 8 months agoLong-established in the Drug Manufacturers industry, Viatris Inc (NASDAQ:VTRS) has enjoyed a stellar...
Mark Cuban has been taking on the drug industry. But which one?
Fortune via Yahoo Finance· 1 year agoWhen billionaire Mark Cuban announced his attack on the pharmaceutical industry and its high-priced...
How expanded use of GLP-1s could affect long-term outlooks for Eli Lilly and Novo Nordisk
Yahoo Finance via AOL· 2 days agoJust a few short years after coming to market, the latest GLP-1 drugs are showing versatility in...
Looking for Passive Income at a Decent Price? Buy These 2 Stocks
Motley Fool· 11 months agoMany investors would love to buy passive income stocks with a high dividend yield, a sustainable...
Is Viatris Inc. (VTRS) Modestly Overvalued?
GuruFocus.com via Yahoo Finance· 9 months agoWith a daily gain of 6.56% and a three-month gain of 22.89%, Viatris Inc. (NASDAQ:VTRS) has been catching the attention of investors. The company's...
